Heat Biologics Inc. [NASDAQ: HTBX] closed the trading session at $1.24 on 09/01/20. The day’s price range saw the stock hit a low of $1.21, while the highest price level was $1.33. The company report on August 26, 2020 that Heat Biologics Announces Publication of Preclinical COVID-19 Vaccine Results.
Heat Biologics, Inc. (“Heat”) (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced publication of positive preclinical COVID-19 results in bioRxiv, which is available at: https://www.biorxiv.org/content/10.1101/2020.08.24.265090v1.
Publication highlights for Heat’s gp96 based COVID-19 vaccine (gp96-Ig-S): .
The stocks have a year to date performance of 161.05 percent and weekly performance of -6.77 percent. The stock has been moved at 51.22 percent over the last six months. The stock has performed -40.38 percent around the most recent 30 days and changed 49.04 percent over the most recent 3-months.
If compared to the average trading volume of 30.99M shares, HTBX reached to a volume of 10017245 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Heat Biologics Inc. [HTBX]:
ROTH Capital have made an estimate for Heat Biologics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 20, 2016. While these analysts kept the previous recommendation, Noble Financial raised their target price to Buy. The new note on the price target was released on January 08, 2016, representing the official price target for Heat Biologics Inc. stock. Previously, the target price had yet another raise to $13, while H.C. Wainwright analysts kept a Buy rating on HTBX stock.
The Average True Range (ATR) for Heat Biologics Inc. is set at 0.22, with the Price to Sales ratio for HTBX stock in the period of the last 12 months amounting to 48.70. The Price to Book ratio for the last quarter was 2.30, with the Price to Cash per share for the same quarter was set at 0.34.
HTBX stock trade performance evaluation
Heat Biologics Inc. [HTBX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -6.77. With this latest performance, HTBX shares dropped by -40.38% in over the last four-week period, additionally plugging by 51.22% over the last 6 months – not to mention a rise of 142.90% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HTBX stock in for the last two-week period is set at 42.86, with the RSI for the last a single of trading hit 34.63, and the three-weeks RSI is set at 42.95 for Heat Biologics Inc. [HTBX]. The present Moving Average for the last 50 days of trading for this stock 1.6343, while it was recorded at 1.2840 for the last single week of trading, and 0.8079 for the last 200 days.
Heat Biologics Inc. [HTBX]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Heat Biologics Inc. [HTBX] shares currently have an operating margin of -636.11. Heat Biologics Inc.’s Net Margin is presently recorded at -656.51.
Return on Total Capital for HTBX is now -85.58, given the latest momentum, and Return on Invested Capital for the company is -87.94. Return on Equity for this stock declined to -91.28, with Return on Assets sitting at -34.96. When it comes to the capital structure of this company, Heat Biologics Inc. [HTBX] has a Total Debt to Total Equity ratio set at 14.21. Additionally, HTBX Total Debt to Total Capital is recorded at 12.44, with Total Debt to Total Assets ending up at 3.58. Long-Term Debt to Equity for the company is recorded at 12.25, with the Long-Term Debt to Total Capital now at 10.72.
Reflecting on the efficiency of the workforce at the company, Heat Biologics Inc. [HTBX] managed to generate an average of -$556,044 per employee. Receivables Turnover for the company is 96.00 with a Total Asset Turnover recorded at a value of 0.05.Heat Biologics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.70 and a Current Ratio set at 7.70.
Earnings per share (EPS) analysis for Heat Biologics Inc. [HTBX] stock
With the latest financial reports released by the company, Heat Biologics Inc. posted -0.18/share EPS, while the average EPS was predicted by analysts to be reported at -0.14/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -28.60%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for HTBX.
Heat Biologics Inc. [HTBX]: Insider Ownership positions
There are presently around $13 million, or 13.00% of HTBX stock, in the hands of institutional investors. The top three institutional holders of HTBX stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 3,032,074, which is approximately 68.581% of the company’s market cap and around 6.04% of the total institutional ownership; MAGNUS FINANCIAL GROUP LLC, holding 2,246,595 shares of the stock with an approximate value of $2.79 million in HTBX stocks shares; and VANGUARD GROUP INC, currently with $2.78 million in HTBX stock with ownership of nearly 6.705% of the company’s market capitalization.
Positions in Heat Biologics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 20 institutional holders increased their position in Heat Biologics Inc. [NASDAQ:HTBX] by around 4,666,871 shares. Additionally, 6 investors decreased positions by around 1,735,093 shares, while 0 investors held positions by with 4,089,068 shares. The mentioned changes placed institutional holdings at 10,491,032 shares, according to the latest SEC report filing. HTBX stock had 9 new institutional investments in for a total of 225,459 shares, while 3 institutional investors sold positions of 141,650 shares during the same period.